BIRMINGHAM, Ala., Nov. 17 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. today announced that it is offering to sell, subject to market and other conditions, 5,000,000 shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. BioCryst also intends to grant the underwriters a 30-day option to purchase up to an aggregate of 750,000 additional shares of common stock to cover over-allotments, if any. All of the shares in the offering are to be sold by BioCryst. Morgan Stanley will be acting as the sole book-runner for the offering, with JMP Securities and Oppenheimer & Co. acting as co-managers.
The issuer has filed a registration statement (including a base prospectus) with the Securities and Exchange Commission, or SEC, for an offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and related prospectus supplements and other documents that the issuer has filed or will file with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, you may obtain a preliminary prospectus supplement and accompanying prospectus as indicated above.
BCRXW
CONTACT: Robert Bennett, BioCryst Pharmaceuticals, +1-919-859-7910
Web site: http://www.biocryst.com/